First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial.

Lisa PascholdAlexander SteinBenjamin ThieleJoseph TintelnotSvenja-Sibylla HenkesCornelia CoithChristoph SchultheißKlaus PantelSabine RiethdorfMascha Binder

Published in: Journal for immunotherapy of cancer (2023)

Prospective validation of this liquid biomarker triad is needed to molecularly define HER2+ EGA patient subsets with different needs in the first-line systemic treatment setting.

Keyphrases

squamous cell carcinoma
locally advanced
ionic liquid
small cell lung cancer
case report
study protocol
clinical trial
radiation therapy
phase iii
phase ii
combination therapy
open label